{"id":7300,"date":"2021-11-15T00:00:00","date_gmt":"2021-11-14T23:00:00","guid":{"rendered":"https:\/\/instrid.sk\/uncategorized\/paxlovid-pfizer\/"},"modified":"2021-11-15T00:00:00","modified_gmt":"2021-11-14T23:00:00","slug":"paxlovid-pfizer","status":"publish","type":"post","link":"https:\/\/instrid.sk\/en\/archiv\/paxlovid-pfizer\/","title":{"rendered":"COVID-19: Liek Paxlovid od Pfizeru zni\u017euje \u0161ancu na hospitaliz\u00e1ciu a \u00famrtie o takmer 90%"},"content":{"rendered":"

Pfizer po vakc\u00edne\u00a0Corminaty prich\u00e1dza \u00a0s nov\u00fdm liekom, ktor\u00fd nesie n\u00e1zov Paxlovid. Spolo\u010dnos\u0165 uviedla pote\u0161uj\u00facu spr\u00e1vu- antivir\u00e1lna tabletka zni\u017euje \u0161ance na hospitaliz\u00e1ciu a smr\u0165 v d\u00f4sledku COVID-19 a\u017e o 90% u rizikov\u00fdch dospel\u00fdch.<\/strong><\/p>\n

Vedci z cel\u00e9ho sveta hraj\u00fa ak\u00e9si pomyslen\u00e9 preteky v tom, kto z nich vyn\u00e1jde tabletku proti COVID-19, ktor\u00fa si pacient bude m\u00f4c\u0165 vzia\u0165 z pohodlia domova, aby zmiernil svoje sympt\u00f3my, ur\u00fdchlil rekonvalescenciu a zmen\u0161il tak bremeno, ktor\u00e9 musia nies\u0165 lek\u00e1ri a nemocnice.<\/p>\n

Paxlovid sa tak zd\u00e1 by\u0165 ve\u013emi n\u00e1dejn\u00fdm prostriedkom na boj s ochoren\u00edm COVID-19.<\/p>\n

Ako dopadlo testovanie lieku Paxlovid<\/h3>\n

Pfizer u\u017e zverejnil predbe\u017en\u00e9 v\u00fdsledky \u0161t\u00fadie, do ktorej bolo zapojen\u00fdch 775 dospel\u00fdch \u013eu\u010foch. Pacientom, ktor\u00fdm bol kr\u00e1tko po objaven\u00ed sa sympt\u00f3mov COVID-19 podan\u00fd Paxlovid spolu s \u010fal\u0161\u00edm antivirotikom, sa redukovali kombinovan\u00e9 \u0161ance na hospitaliz\u00e1ciu alebo \u00famrtie v s\u00favislosti koronav\u00edrusu o 89% v porovnan\u00ed s pacientmi, ktor\u00fdm bolo podan\u00e9 placebo.<\/strong><\/p>\n

Menej ako 1% pacientov, ktor\u00fdm bol podan\u00fd Paxlovid, potrebovalo hospitaliz\u00e1ciu a nikto z nich neumrel.<\/strong> V skupine pacientov, ktor\u00fdm bolo podan\u00e9 placebo, boli v\u00fdsledky hor\u0161ie. 7% \u013eud\u00ed potrebovalo hospitaliz\u00e1ciu a 7 pacientov umrelo.<\/p>\n

"D\u00fafali sme, \u017ee sme objavili nie\u010do v\u00fdnimo\u010dn\u00e9, ale je ve\u013emi vz\u00e1cne vidie\u0165 lieky, ktor\u00e9 prejd\u00fa testovan\u00edm s takmer 90% \u00fa\u010dinnos\u0165ou a 100% ochranou pred \u00famrt\u00edm,<\/em>\u201c prezradil Doktor Mikael Dolsten, ved\u00faci vedeck\u00fd pracovn\u00edk spolo\u010dnosti Pfizer.<\/p>\n

\u00da\u010dastn\u00edci \u0161t\u00fadie neboli zao\u010dkovan\u00ed, ich sympt\u00f3my boli od miernych po stredne z\u00e1va\u017en\u00e9, pri\u010dom mali vysok\u00e9 riziko hospitaliz\u00e1cie kv\u00f4li zdravotn\u00fdm probl\u00e9mom ako obezita, cukrovka alebo ochorenia srdca.<\/strong> Lie\u010dba za\u010dala od 3 a\u017e 5 dn\u00ed od objavenia sa prv\u00fdch pr\u00edznakov ochorenia COVID-19 a trvala 5 dn\u00ed. Pacienti, ktor\u00ed tabletku dostali sk\u00f4r mali o nie\u010do lep\u0161ie v\u00fdsledky. Tieto zistenia pod\u010diarkli potrebu r\u00fdchleho testovania a n\u00e1slednej lie\u010dby.<\/p>\n

Pfizer uviedol aj nieko\u013eko detailov oh\u013eadom ved\u013eaj\u0161\u00edch \u00fa\u010dinkov lieku. Asi 20% probl\u00e9mov bolo rovnak\u00fdch v oboch skupin\u00e1ch <\/strong>(skupina, ktor\u00e1 dostala liek verzus skupina, ktor\u00e1 dostala placebo).<\/p>\n

Nez\u00e1visl\u00e1 skupina medick\u00fdch expertov, ktor\u00e1 monitorovala testovanie lieku, odporu\u010dila, aby bolo \u010doskoro ukon\u010den\u00e9.<\/strong> Je to \u0161tandardn\u00fd postup v pr\u00edpade, \u017ee predbe\u017en\u00e9 v\u00fdsledky uk\u00e1\u017eu pr\u00ednos lieku takto jasne. D\u00e1ta e\u0161te nie s\u00fa spr\u00edstupnen\u00e9 na extern\u00e9 presk\u00famanie, \u010do je taktie\u017e be\u017en\u00fdm procesom preverovania nov\u00e9ho lek\u00e1rskeho v\u00fdskumu.<\/p>\n

Vakcin\u00e1cia st\u00e1le zostane najlep\u0161\u00edm sp\u00f4sobom ochrany pred infekciou. Objavom tohto lieku by v\u0161ak bola lie\u010dba infekcie efekt\u00edvnej\u0161ia a jednoducho pou\u017eite\u013en\u00e1. Objav takejto lie\u010dby je rozhoduj\u00facim v potla\u010den\u00ed pr\u00edpadn\u00fdch \u010fal\u0161\u00edch v\u013an ochorenia COVID-19.<\/strong><\/p>\n Predbe\u017en\u00e9 v\u00fdsledky testovania lieku Paxlovid dopadli pote\u0161uj\u00faco, takmer 90% pacientov sa vyhlo hospitaliz\u00e1cii \u010di smrti, Zdroj: Unsplash\/Mufid Majnun\n

Paxlovid a \u010fal\u0161ie lieky proti COVID-19<\/h3>\n

Na Slovensku moment\u00e1lne EMA posudzuje liek Molnupiravir od spolo\u010dnosti Merck Sharp & Dohme (MSD). Toto antivirotikum, ktor\u00e9 taktie\u017e sl\u00fa\u017ei na lie\u010dbu COVID-19, je zatia\u013e podmiene\u010dne schv\u00e1len\u00e9 len v jednej krajine- vo Ve\u013ekej Brit\u00e1nii. Spolo\u010dnos\u0165 e\u0161te v septembri 2021 vyhl\u00e1sila, \u017ee Molnupiravir zni\u017euje riziko hospitaliz\u00e1cie a smrti v d\u00f4sledku ochorenia COVID-19 o 50%. Experti v\u0161ak varuj\u00fa pred porovn\u00e1van\u00edm predbe\u017en\u00fdch v\u00fdsledkov Molnupiraviru a Paxlovidu kv\u00f4li odli\u0161nostiach v \u0161t\u00fadi\u00e1ch.<\/strong><\/p>\n

Pfizer by v\u0161ak mohol \u0165a\u017ei\u0165 zo svojho bezpe\u010dnostn\u00e9ho profilu. Zatia\u013e \u010do do testovania Molnupiraviru neboli zapojen\u00e9 tehotn\u00e9 \u017eeny<\/strong> kv\u00f4li potenci\u00e1lnemu risku vroden\u00fdch v\u00e1d, Pfizer tak\u00e9to obmedzenia pri testovan\u00ed nezaviedol.<\/p>\n

Paxlovid je liekom, ktor\u00fd je s\u00fa\u010das\u0165ou desiatky rokov starej \u201erodiny antiv\u00edrusov\u00fdch liekov\u201c zn\u00e1mych ako inhib\u00edtory prote\u00e1zy. Pr\u00e1ve tieto lieky zapo\u010dali revol\u00faciu v lie\u010dbe HIV a hepatit\u00eddy C.<\/strong> Tak\u00e9to lieky blokuj\u00fa k\u013e\u00fa\u010dov\u00fd enz\u00fdm, ktor\u00fd v\u00edrusy potrebuj\u00fa na to, aby sa v \u013eudskom tele dok\u00e1zali rozmno\u017eova\u0165.<\/p>\n

Tento liek bol po prv\u00fdkr\u00e1t identifikovan\u00fd po\u010das vypuknutia SARS s p\u00f4vodom v \u00c1zii v roku 2003. V\u00fdskumn\u00edci spolo\u010dnosti Pfizer sa minul\u00fd rok rozhodli, \u017ee liek o\u017eivia a presk\u00famaj\u00fa ho v s\u00favislosti s COVID-19 nako\u013eko s\u00fa si tieto dva koronav\u00edrusy podobn\u00e9.<\/p>\n

Sources: <\/strong>Time, Pfizer, The Indian Express, Webnoviny<\/p>\n

Zdroj titulnej fotografie:<\/strong> Pixabay\/Pexels\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

Pfizer po vakc\u00edne\u00a0Corminaty prich\u00e1dza \u00a0s nov\u00fdm liekom, ktor\u00fd nesie n\u00e1zov Paxlovid. Spolo\u010dnos\u0165 uviedla pote\u0161uj\u00facu spr\u00e1vu- antivir\u00e1lna tabletka zni\u017euje \u0161ance na hospitaliz\u00e1ciu a smr\u0165 v d\u00f4sledku<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[51],"tags":[],"class_list":["post-7300","post","type-post","status-publish","format-standard","hentry","category-archiv","two-columns"],"_links":{"self":[{"href":"https:\/\/instrid.sk\/en\/wp-json\/wp\/v2\/posts\/7300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/instrid.sk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/instrid.sk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/instrid.sk\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/instrid.sk\/en\/wp-json\/wp\/v2\/comments?post=7300"}],"version-history":[{"count":0,"href":"https:\/\/instrid.sk\/en\/wp-json\/wp\/v2\/posts\/7300\/revisions"}],"wp:attachment":[{"href":"https:\/\/instrid.sk\/en\/wp-json\/wp\/v2\/media?parent=7300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/instrid.sk\/en\/wp-json\/wp\/v2\/categories?post=7300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/instrid.sk\/en\/wp-json\/wp\/v2\/tags?post=7300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}